Back to Search
KIERON DUNLEAVY, MD
MD
Medical Oncology Physician
NPI: 1154610467IndividualAccepts Medicare
Education
OTHER
Class of 1994
Research & Publications (20)
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
PMID 19380866·Blood·2009
4-observational
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
PMID 18378569·J Clin Oncol·2008
3-trial
Angioimmunoblastic T-cell lymphoma (AILT): a unique clinical and pathobiological entity.
PMID 18854648·Onkologie·2008
8-other
The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma.
PMID 17577765·Leuk Lymphoma·2007
8-other
Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications.
PMID 17534160·Curr Opin Hematol·2007
6-review
Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy.
PMID 17454581·Leuk Lymphoma·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3800 RESERVOIR RD NW
WASHINGTON, DC 20007 - Phone
- (202) 444-3736
Quick Facts
- NPI
- 1154610467
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile